Non-Hodgkin Lymphoma (NHL)

Lymphoid Neoplasms
Non-Hodgkin Lymphoma (NHL)
- Aggressive (MCL, DLBCL, Burkitt, Richters)
  - Newly Diagnosed
  - VICC-DTCTT24008
    ALPHA3: Ph2 Study of ALLO-501A in Participants w/MRD After Response to 1L Tx for DLBCL
  - Autologous Transplant
  - Relapsed/Refractory
    - VICCCTT25034
      Phase 1/2 Study of LYL314 in Participants with Aggressive B-Cell Non-Hodgkin Lymphoma
    - VICCHEMP25075
      NOVA-BCL6-1, Phase 1a/1b Study of LY4584180 in Adults with Previously Tx Hematologic Malignancies
  - Early First Relapse (less than 12 mos.)
    - No Current Trials
  - CAR-T Failure
    - No Current Trials
- Indolent (FL, CLL, MZL)
  - Newly Diagnosed
  - Relapsed /Refractory
    - VICC-ITCTT23024
      A Phase 2, Open-Label, Study Evaluating Safety and Efficacy of the Loncastuximab in R/R MZL
    - VICCHEMP25075
      NOVA-BCL6-1, Phase 1a/1b Study of LY4584180 in Adults with Previously Tx Hematologic Malignancies
  - CAR-T Failure
    - No Current Trials
- T-Cell
- VICC-DTCTT23454
  A Phase III Trial of Tac/MTX/Rux vs PTCy/Tac/MMF in RIC Allogeneic PBSC Transplantation
- CIBMTRCTT25029
  Platform Protocol to Investigate PTCy-Based GVHD PPx in Patients w HM Undergoing MMUD PBSCT
- Mantle Cell Lymphoma
  - ETCPCL10702
    Phase II Study of Glofitamab for R/R MCL in Pts Previously Treated w/CD19-Directed CAR T-Cell Tx
    - 1. Patients must have histologically or cytologically confirmed diagnosis of mantle cell lymphoma that is relapsed (disease progression after the last treatment regimen) or refractory (failure to achieve a partial or complete response from the last treatment regimen).
      2. Patients must have been previously treated with an anti-CD19 CAR T-cell therapy and have failed or been intolerant to BTK inhibition. Both commercial and investigational CAR-T products which target CD19 will be allowed, including dual-targeting products.
      3. Patients must have at least one bi-dimensionally measurable (defined as at least 1.5 cm) nodal lesion or one bi-dimensionally measurable (at least 1 cm) extranodal lesion, as measured on CT scan.
      4. ECOG performance status </=2 (Karnofsky >/=60%, see Appendix A).